Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models

Carmen Blanco-Aparicio¹, Marta Cañamero², Yolanda Cecilia², Belén Pequeño¹, Oliver Renner¹, Irene Ferrer¹, Amancio Carnero¹*¤

¹ Experimental Therapeutics Programme, Spanish National Cancer Research Centre, Madrid, Spain, ² Biotechnology Programme, Spanish National Cancer Research Centre, Madrid, Spain

Abstract
Elevated expression of AKT has been noted in a significant percentage of primary human breast cancers, mainly as a consequence of the PTEN/PI3K pathway deregulation. To investigate the mechanistic basis of the AKT gain of function-dependent mechanisms of breast tumorigenesis, we explored the phenotype induced by activated AKT transgenes in a quantitative manner. We generated several transgenic mouse lines expressing different levels of constitutively active AKT in the mammary gland. We thoroughly analyzed the preneoplastic and neoplastic mammary lesions of these mice and correlated the process of tumorigenesis to AKT levels. Finally, we analyzed the impact that a possible senescent checkpoint might have in the tumor promotion inhibition observed, crossing these lines to mammary specific p53(R172H) mutant expression, and to p27 knock-out mice. We analyzed the benign, pre-malignant and malignant lesions extensively by pathology and at molecular level analysing the expression of proteins involved in the PI3K/AKT pathway and in cellular senescence. Our findings revealed an increased preneoplastic phenotype depending upon AKT signaling, which was not altered by p27 or p53 loss. However, p53 inactivation by R172H point mutation combined with myrAKT transgenic expression significantly increased the percentage and size of mammary carcinoma observed, but was not sufficient to promote full penetration of the tumorigenic phenotype. Molecular analysis suggested that tumors from double myrAKT;p53(R172H) mice result from acceleration of initiated p53(R172H) tumors and not from bypass of AKT-induced oncogenic senescence. Our work suggests that tumors are not the consequence of the bypass of senescence in MIN. We also show that AKT-induced oncogenic senescence is dependent of pRb but not of p53. Finally, our work also suggests that the cooperation observed between mutant p53 and activated AKT is due to AKT-induced acceleration of mutant p53-induced tumors. Finally, our work shows that levels of activated AKT are not essential in the induction of benign or pre-malignant tumors, or in the cooperation of AKT with other tumorigenic signals such as mutant p53, once AKT pathway is activated, the relative level of activity seems not to determine the phenotype.

Introduction
The PTEN/PI3K pathway is one of the most altered in cancer. PTEN activity is lost by mutations, deletions or promoter methylation silencing at high frequency in many primary and metastatic human cancers [1,2]. Germline mutations of PTEN are found in Cowden, Bannayan-Riley-Ruvalcaba and a Proteus –like syndromes, all of them familial cancer predisposition syndromes [3,4,5,6]. The PI3KCA gene (coding for the p110α catalytic subunit of PI3K) have been described to be highly mutated in human tumors [2,7]. The most frequently observed PI3K kinase mutations showed enhanced catalytic activity [8], able to constitutively activate AKT and produce transcriptional activation. It has also been reported an AKT1 somatic mutation in human breast, colorectal and ovarian cancers. This mutation activates AKT by means of pathological localization to the plasma membrane, stimulates downstream signaling, transforms cells and induces leukemia in mice [9]. Activation without mutations of PI3K and AKT are reported to occur in breast [10,11,12], ovarian [11,13,14], pancreatic [15], esophageal [16], thyroid cancer [17] and other cancers [2,18].

Loss of PTEN function, as well as PI3K activation (either by growth factors or oncogenic mutations), results in accumulation of PIP3 triggering the activation of its downstream effectors, PDK1 and AKT. AKT activation stimulates cell cycle progression, survival, metabolism and migration through phosphorylation of many physiological substrates [19] [20,21]. Deletion of AKT1 reversed the survival phenotype in PTEN null cells and abrogated its growth advantage [22]. Similarly, inactivation of AKT by dominant negative mutants inhibits the survival advantage provided by activated class I PI3K [23]. Disruption of AKT inhibits ErbB2-induced mammary tumorigenesis [24]. AKT1 deficiency delayed tumor growth and reduced metastasis. AKT1 null mammary epithelial tumor cells have also reduced prolifer-
tumors from double myrAKTp53(R172H) mice proceed from acceleration of initiated p53[R172H] tumors and not from bypass of oncogenic-induced senescence induced by activated AKT.

Results

Transgenic myrAKT Lines

We generated several AKT-activated transgenic lines as previously described [27]. The different lines present variability in both, the levels of expression of activated AKT and the degree of chimaerism, number of cells per duct expressing the transgene. Out of 7 expressing transgenic lines we selected 3 of them, EA5, EA2 and EA4 that showed different levels of AKT activation (measured as AKT phosphorylation at S473) (Figure 1). We quantified the value of AKT activation and observed that EA5 line showed low AKT activation, just above the basal levels, however, EA2 and EA4 showed at least 5–7 fold activation. Due to chimaerism observed in most transgenic lines at difference from knock-ins models, the ducts also expressed variable percentage of cells expressing the transgene (Figure 1A and D). While EA5 showed low number of cells with the transgene, EA2 and EA4 presented an average of 60% cells per duct with AKT activated (Figure 1A). We did also generate the homozygous transgenic lines expressing two alleles of activated AKT. AKT levels increase in such homozygous lines (Fig 1C) although they do not double the levels of AKT activation. Similarly, homozygous lines increased the number of cells per duct expressing the transgene (Figure 1A).

Tumor Phenotype of Transgenic myrAKT Lines

The levels of AKT activation measured as S473 phosphorylation were functional in all lines, since mammary gland involution was delayed in all transgenic lines (Figure S1). However, despite genetic (one or two alleles) of physiological (virgin or multiparous) differences that contribute to different levels of AKT and chimaerism, no differences in the survival of transgenic lines were observed (Data not shown). We did not observe a statistical increase in the number of mammary tumors in any of the transgenic lines.

An in deep analysis of the mammary glands of the animals indicated that the transgenic lines showed an increased percentage of intraductal mammary neoplasia (MIN) and suckling differentiation (Figure 2). This increase was observed in all transgenic lines without a clear correspondence with AKT levels or degree of chimaerism, indicating that high levels of AKT are not essential. Only a higher incidence of MIN in almost all transgenic lines is correlated with no pregnancies. A few animals with tumors were also observed, of variable type, with no statistical significance (Figure 2).

The molecular characterization of MIN indicated that MIN from wild type animals were different from to those arising in transgenic mammary glands. Transgenic MIN showed increased AKT phosphorylation and were positive for Progesterone receptor (PR), Estrogen Receptor (ER) and Estrogen Receptor phosphorylation (ER-P) (Figure S2).

The few tumors arising from transgenic animals were histologically heterogeneous but could be grouped in two main
classes: adenosquamous (n = 1) and carcinomas of different types (n = 4) (Figure 2). Staining for molecular markers showed that carcinomas presented in general similar molecular pattern (Figure S2). All of them showed AKT phosphorylation and increased levels of ER, ER-P and PR. They also showed strong keratin 6 (CK6), E-cadherin and p63 staining.

Taken together our data indicated that increasing the levels of AKT in the mammary gland was not sufficient to produce a tumoral response in mice. Only a moderate increase in premalignant lesions was observed, and this was independent of the levels of AKT and the degree of chimaerism in the ductal epithelia.

Senescence Markers

It has been proposed that the activation of AKT triggers a senescent checkpoint blocking the progression to full grown tumors [30,32]. Therefore, we have explored whether premalignant lesions expresses senescent markers and whether these are lost in tumors (Figure 3). MIN from myrAKT transgenes clearly over expresses p19ARF, p21cip1 (here p21) and HP1γ markers of senescence. But these markers are maintained at similar levels in carcinomas (Figure 3). These markers are not expressed at similar levels in MIN from wild type animals suggesting specific oncogenic-induced senescent signals (Figure S3). On the other hand, p16INK4a (p16) is slightly induced in MIN from transgenic animal and lost in carcinomas (Figure 3) suggesting that Rb pathway may be a more important senescent checkpoint than p53 in AKT-derived tumors. To confirm this point we analyzed p53 stabilization as a correlate for p53 mutation by immunohistochemistry since it has been observed that most p53 mutations appear as strong nuclear p53 staining. Especially in p53 heterozygous mouse models, LOH generally occurs by p53 mutations. We observed that neither MIN nor macroscopic carcinomas showed p53 stabilization reflected by the low levels of

Figure 1. Expression of AKT-P S473 in the mammary gland of nulliparous and multiparous transgenic mice. (A) Percentage of ductal mammary cells stained with AKT-P in heterozygous and homozygous nulliparous transgenic mice and wild-type littersmates. (B) Immunohistochemical detection of phosphoS473 AKT1 in mammary glands of heterozygous and homozygous nulliparous transgenic mice and wild-type littersmates. (C) Quantification of staining intensity of phosphoS473 AKT1 in mammary glands of heterozygous and homozygous nulliparous transgenic mice and wild-type littersmates. (D) Percentage of ductal mammary cells stained with AKT-P in heterozygous multiparous transgenic mice and wild-type littersmates. (E) Immunohistochemical detection of phosphoS473 AKT1 in mammary glands of heterozygous multiparous transgenic mice and wild-type littersmates. (F) Quantification of staining intensity of phosphoS473 AKT1 in mammary glands of heterozygous multiparous transgenic mice and wild-type littersmates. The staining in epithelial cells was quantified using the NIH ImageJ software package. The difference between transgenic and wt is displayed as relative Intensity vs wt. P-value is 0.05 (unpaired Student’s t test).
nuclear p53 expression, correlating with wild type p53 (Figure 3). This result points to the existence of a tumor progression barrier different to p53.

P27 Loss Does Not Contribute to AKT-Dependent Tumorigenesis

To explore whether a p27-dependent checkpoint induces senescence upon AKT activation, and that the ablation of this checkpoint, allows the progression from MIN to carcinoma, as has been suggested in prostate models [31], first, we checked whether p27 was activated in benign lesions and/or lost in tumors (adenosquamous or carcinoma) in our myrAKT mice. Immunohistochemistry staining showed that p27 was expressed in the normal mammary glands of wild type and AKT mice (Figure S4). The levels seemed increased in MIN from normal or myrAKT mice (Figure S4), although p27 levels were similar in both cases. However, these high p27 levels were maintained in carcinoma from myrAKT mice (Figure S4), indicating that p27 barrier was overcame during the process of tumorigenesis.

To complement the study whether p27 might play a role inhibiting the growth of AKT derived tumors we expressed myrAKT transgene into p27 heterozygous and null backgrounds. MyrAKT;p27(−/−) mice develop pituitary tumors early in life and died without the possibility of studying the role of p27 absence in the mammary gland (Data not shown). Since p27 can also act as tumor suppressor in haplinsufficiency we explored this possibility in our myrAKT mice. MyrAKT;p27(+/-) mice died slightly earlier than myrAKT mice, however, no mammary tumors were observed (Not shown). The analysis of the branching of mammary glands in these mice showed similar pattern than myrAKT, without further progression towards the tumoral phenotype (Figure S4). Our data suggest that although p27 might contribute to the AKT induced senescence it is not the primary determinant of arrest for these cells to stop growth in mammary gland.

However, given the correlative and not conclusive nature of these results, additional studies using tissue specific deletion of p27 in AKT-activated background are necessary to further strengthen this assertion.

P53 Mutant Expression Cooperated with AKT Activation in the Generation of Breast Carcinoma

It has been proposed that AKT activation triggers senescence in primary cells and that this tumor suppressor mechanism might be dependent on the presence of p53 [29] [30]. However, our data from MIN and tumors of myrAKT models suggest that p53 pathway is not involved in the pre to malignant progression.
However, other tumor models, such as head and neck, show p53 and AKT cooperation in tumorigenesis [33,34].

To further explore whether this mechanism plays a role in our experimental system, we generated mice carrying the activated AKT transgene and the mutant p53(R172H) in the mammary ductal epithelia by crossing the MMTV-myrAKT with the wap-p53(R172H) line. Double heterozygous transgenes were analyzed in deep. Neither, total survival nor survival of mice with mammary tumors was altered in these mice (Figure 4). And the range of preneoplastic lesions did not vary in doubles myr-AKT;p53(R172H) from p53 mutant mice alone (Figure 4). We observed that while p53(R172H) transgenic mice did not show

**Figure 3. Expression of senescence markers in MIN and mammary tumors of myrAKT mice.** Immunohistochemical staining of MIN and tumors with p19, p21, p16, Heterochromatin 1 gamma (HP1-γ) and p53. A 200× magnification was used and 400× magnification was inserted in the corner.

doi:10.1371/journal.pone.0009305.g003
Figure 4. Survival and characterization of alteration in mammary gland of p53R172H transgenic mice. A) Tumor-free survival curves in p53R172H and p53R172H:myr-AKT transgenic mice. Survival curves were computed using the Kaplan-Meier product-limit method. The numbers of mice are the following: p53R172H transgenic mice (n = 16); p53R172H:myr-AKT transgenic mice (n = 18). B) Survival of mice that have developed mammary gland tumors. The numbers of mice are the following: p53R172H transgenic mice (n = 8); p53R172H:myr-AKT transgenic mice (n = 11). C) Mammary gland phenotypes of the p53R172H transgenic mouse lines observed after death. Whole mammary glands of dead or sacrificed (humane end point) mice were stained with carmine red to visualize the structure of the ducts and alveoli. Three different categories of phenotypes could be distinguished: (1) normal structure similar to the one of involuted multiparous female mice; (2) Cystic dilation (of the ducts) of more than 4 time; (3) increased number of ramifications and strongly increased alveolar size. Points, median of each mouse cohort. In all cases, mice with pituitary tumors were not considered. D) Incidence of preneoplastic and neoplastic lesions in p53R172H and p53R172H:myr-AKT transgenic mice. E) Immunohistochemical staining of MIN and tumors with p19, p21, p16, Heterochromatin 1 gamma (HP1-γ) and p53. A 200× magnification was used and 400× magnification was inserted in the corner.

doi:10.1371/journal.pone.0009305.g004
MIN, doubles myrAKT;p53(R172H) showed 40% mice carrying MIN, percentage similar to the observed in virgin myrAKT transgenic lines (Figure 4). The transgenic lines with p53(R172H) are multiparous and the incidence of MIN in double transgenic line is equivalent to the virgin myrAKT mice. Identical data was observed when myrAKT transgene was expressed in a p53(+/-) heterozygous background in virgin females (Figure S5). Therefore, p53 mutant does not alter the MIN to carcinoma transition in myrAKT1 transgenics. Moreover, multiparous females that expressed p53 mutant and myrAKT reached levels of MIN equivalent to virgin females.

To explore the role of p53 in AKT-dependent MIN we compared the behavior of senescent markers p19ARF, p21 or p53 in MIN from myrAKT in wild type or p53(R172H) mutant backgrounds (Figure 4D), or in p53(+/-) heterozygous background (Figure S6). P19ARF is increased in all lines. However, it shows different levels among the different lines, being greatly overexpressed in the presence of mutant p53 as expected. p21 was equally increased in all lines while p53 showed clear staining in both lines expressing the mutant p53(R172H).

Although we did observed a 30% p53(R172H) mice with carcinomas, the number of mice with carcinoma in doubles myrAKT;p53(R172H) increased to 80% (Figure 5A), tumors that showed bigger size. While in p53(R172H) mice carcinomas showed an average size of less than 0.03 cm³, in double myrAKT;p53(R172H) mice, carcinomas had an average volume of 0.2 cm³ (Figure 5B and C). Both however, showed clear p53 staining (confirming p53(R172H) mutant expression). Double myrAKT;p53(R172H) tumors also showed activated AKT, but in general the levels were lower than in myrAKT only tumors.

These data indicated that activated AKT cooperated with p53 mutant increasing the number and size of carcinomas but not the number of premalignant lesions, suggesting a more aggressive phenotype instead of a predisposition to develop a malignant lesion. However, the number of premalignant lesions, especially MIN, do not decrease as consequence of the transition to carcinoma, nor the double myrAKT;p53(R172H) transgenic mice showed full penetrance phenotype despite broad expression of transgenes in mammary ducts. Together with the data of no mutations in the p53, or p19ARF in tumors from myrAKT suggest that the constitutive activation of AKT induced a senescent barrier that is independent of p53. Therefore, the mutant p53-AKT observed cooperation might be due to an increase in proliferation induced by AKT activation in p53(R172H)-induced carcinomas.

To explore this possibility we compared the different tumors arising in the different cohorts. These tumors were analyzed immunohistologically for a set of common mammary tumor markers and evaluated by double blind observations by 2 independent pathologists. Discrete values between 0 (no expression) and 3 (higher levels) was assigned to each tumor and the correlation between different tumors analyzed by using the function helcluster (package amap) of the free statistical software R. The different tumors analyzed showed very high pathological variability across all transgenic lines. Carcinomas and adenocarcinomas with different degrees of mixed, glandular, acinar or solid pathological features were observed in all lines. No specific morphological pattern was assigned to any genetic background (Figure 5D). We observed that while AKT levels were very high (3) in all myrAKT tumors, tumors from double myrAKT;p53(R172H) transgenic mice were more heterogeneous but in general showed lower levels of activated AKT (Figure 5D, Figure S7). Furthermore, ER phosphorylation but not ER expression was associated with AKT activation in agreement with previous results indicating the relevance of ER phosphorylation by AKT [35] [36] [27] [26]. All tumors showed clear E-cadherin staining as reflection of their epithelial origin. CK6, nanog, p63, ER y PR are expressed in all myrAKT tumors but only in a very small (aprox 20%) tumors from double myrAKT;p53(R172H), and mostly low levels (Figure S7). However it absence in most double myrAKT;p53(R172H) tumors correlated with the observed in p53(R172H) induced carcinomas (Figure 5D, Figure S7). Furthermore, p63, CK6 and nanog levels are homogeneous and higher in myrAKT tumors while tumors with mutant p53 (from p53(R172H) and myrAKT;p53(R172H) mouse lines) are heterogeneous and show lower levels of expression of these proteins. ErbB2 (Her2, neu) overexpression is observed in 20-30% human breast cancer [37]. In mouse models loss of PTEN function lead to elevated erbB2 protein levels [38]. We have tested whether in our model AKT activated transgene induced erbb2 protein. Our data showed a few ErbB2 barely positive tumors which correlated with no expression of ER and PR and high histopathological grade. Only one tumor, probably outlayer, showed high ErbB2 positivity.

The overall picture shows that tumors from double myrAKT;p53(R172H) transgenic mice are more close to tumors from p53(R172H), while tumors from myrAKT are different. However, the number of tumors is very small and a much higher number of tumors are necessary to analyze to further support our conclusions.

Taken together, our experiments suggest that although tumor proliferation may be blocked by the presence of wild type p53, p53-dependent senescence might not be the only tumor suppressor mechanism impeding tumorigenesis in the mammary glands of myrAKT transgenic mice. The cooperation observed between activated AKT and mutant p53 seems to indicate that AKT enhances the proliferation of mutant p53-induced tumors.

**Discussion**

Elevated expression of AKT has been noted in a significant percentage of primary human breast cancers, mainly as a consequence of PTEN/P13K pathway deregulation. The PTEN/P13K pathway is probably the most frequently mutated pathway in human cancer. Furthermore, tyrosine kinase membrane receptors are also mutated or activated (ie: ErbB2, EGFR) contributing to AKT deregulation in mammary tumors. Different works analyze the necessity of the AKT signal in mammary tumorigenesis induced by different oncogenic signals (reviewed in [39] [40] [41]). However, the enforced AKT activation found in most mammary tumors suggest that there is also a sufficient signal to promote tumorigenesis. However, this point is still controversial since mammary models do not completely recapitulate the expected tumorigenic phenotype [39].

Several hypotheses, however, have been proposed to explain this apparent phenomenological discrepancy. Transgenic expression of activated AKT does not reach appropriate levels to induce tumorigenesis. Either they are too low to activate oncogenic pathway or too high activating senescence. Enforced AKT activation leads to p53-dependent senescence, like for PTEN loss [29], or p27-dependent senescence [31]. Finally, It is also possible that transgenic AKT activation does not occurs in the appropriated target cell (ie: it is possible that MMTV promoter used in most of the transgenic mouse models it is not activated in the cells susceptible to generate a tumor).

To investigate the mechanistic basis of the AKT-dependent mechanisms of breast tumorigenesis, we have generated several transgenic mice lines expressing different levels of constitutively active AKT in the mammary gland. Mice expressing activated AKT showed an increased percentage of suckling differentiation.
even in nulliparous females. In humans high parity has generally been associated with low breast cancer risk in several epidemiological studies [42] [43] [44]. In mice ablation of AKT1 dramatically delays mammary gland differentiation during pregnancy and lactation and promotes apoptosis and accelerates involution what correlates with defects in Stat5 phosphorylation.
Maybe the expression of an activated AKT promotes a differentiation of the mammary gland that protects from tumor development.

Moreover, we thoroughly analyzed the phenotype of these mice and correlated to the process of tumorigenesis by either preneoplastic or neoplastic lesions. AKT activation increased the number of benign lesions but neither AKT activated levels nor number of cells with AKT activation in the mammary duct correlated with lesion number. Only myrAKT multiparous females from almost all transgenic lines showed an incidence of benign lesions, especially premalignant MIN, lower than nulliparous females. These data suggest that the absence of tumors in AKT-activated mice is not a consequence of inappropriate AKT levels in the transgene. We can also exclude that the AKT is not activated in the right target cells (i.e., cancer prone cell) since we can increase the number of cells per duct with AKT activation in different lines but we cannot observe a parallel increase in benign or malignant lesions. Therefore, our results suggest the existence of a tumor suppressor barrier that prevents tumorigenesis once AKT is activated. Clearly, p53 and p27 dependent senescence are a tumor suppressor barrier that prevents tumorigenesis once AKT is activated. Clearly, p53 and p27 dependent senescence are major mechanisms proposed to achieve this goal.

To explore these mechanisms we have analyzed different molecular markers of senescence in the benign and malignant lesions formed in AKT-activated mice. We have found that p19ARF, p21, p27, p16 and HP1γ seems to be activated in MIN but only p16 disappears in tumors, indicating that pRb might constitute the senescent checkpoint which needs to be overcome in these AKT-dependent lesions to produce tumors. Interestingly, half of tumors containing mutant p53 also lost p16.

To further explore the relevance of p27 and p53 checkpoints, we generated transgenes with activated AKT in p27(+/−), p53(+/−) or p53(R172H) mutant background. Our results revealed that the enhanced AKT-dependent preneoplastic phenotype was not altered by p27 reduction or p53 activity loss. However, p53 inactivation by R172H point mutation combined with myrAKT transgenic expression significantly increased the percentage and size of mammary carcinomas. However it was not sufficient to promote full penetrance of the tumorigenic phenotype.

These data indicated that activated AKT cooperated with p53 mutant increasing the number and size of carcinomas but not the number of premalignant lesions. However, the number of premalignant lesions, MIN, do not decrease as consequence of the transition to carcinoma, nor the double myrAKT;p53(R172H) transgenic mice showed full penetrance phenotype despite broad expression of transgenes in mammary ducts. Moreover, AKT activation in parous females decrease the incidence of MIN, but in the presence of p53 mutant this protection was not observed. Together with the data of no mutations in the p53 nor p19ARF tumors from myrAKT suggest that the constitutive activation of AKT induced a senescent barrier that is independent of p53. Therefore, the mutant p53-AKT observed cooperation might be due to an increase in proliferation induced by AKT activation in p53(R172H)-induced carcinomas. The molecular comparison of tumors from myrAKT, p53(R172H) or double myrAKT;p53(R172H) mice suggests that myrAKT;p53(R172H) tumors seem to proceed from p53(R172H) expressing cells and that AKT accelerated the process of tumorigenesis, rather than from cells with activated AKT where the p38 brake has been eliminated.

On the other hand, R172H p53 mutant, equivalent to human R175H, is a structure defective mutant whose point mutation determines an important conformational alteration [46]. The presence of conformational mutants has been strongly associated with breast cancer patients [47] [48] [49]. Mutant p53 proteins do not represent the mere loss of wild type p53 activity, but gain new additional oncogetic functions which contribute to the development, maintenance and spreading of cancer [46] [50,51] [52]. It has been shown that mutant p53 triggers different pathways that represent the molecular basis of the gain of function activity [52].

These scenarios might favor the increase of MIN detected in multiparous double transgenic mice that do no progress to carcinoma due to the senescence induced by AKT independent of p53. On the other hand, the expression of mutant p53 might contribute to tumor initiation, while active AKT background might contribute to tumor progression through several of the pleiotropic effects induced by AKT activity (Reviewed in [53,54], contributing to the large increase in size observed in carcinomas. On the other hand, increased proliferation can also contribute to the increased number of carcinomas by increasing carcinoma detection.

Taken together, our experiments suggest that although tumor proliferation may be blocked by the presence of wild type p53, p53-dependent senescence might not be the only tumor suppressor mechanism impeding tumorigenesis in the mammary glands of myrAKT transgenic mice. This is confirmed by the lost of p16 in half of tumors with mutated p53.

These data fully agree with our hypothesis that pRb might constitute the main senescent checkpoint which needs to be overcome in these AKT-dependent lesions to produce tumors. This hypothesis also correlated with the works of Yu et al [55], Landis et al [56] and Reddy et al [57] reporting the necessity of CDK4 activity for mammary tumorigenesis. Our data point towards loss of CDK4 inhibitor p16 is the genetic alteration in the hyperplasia to tumor transition in the AKT activated transgene. In fact, previous results from our group showed that activated p110α transgenic expression in CDK4(R24C) mutant background produces an increase in preneoplastic lesions and in tumor formation [26].

In human breast tumors, activation of cyclin D1 is a common event. Amplification of the gene has been detected in about 15% of breast cancers, while overexpression of cyclin D1 at mRNA and protein levels is seen in up to 50% of primary tumors, mostly ER-positive and well-differentiated tumors [58] [59]. Furthermore, joint overexpression of cyclin D and PI3K pathway activation, either directly or indirectly through membrane receptors, is a common event described in human tumors [60] [40,61].

Since breast cancer is notable for the high incidence of cyclin D1 aberrations with up to 50% of tumors expressing elevated levels of the protein (reviewed in [59] [59] [62]), we can expect to find p16 defects among the remaining tumors. To date, there have been reports suggesting that p16 may be affected by methylation in primary breast cancers with quoted frequencies of 15–30% [63] [64] [65] [66] [67] and there is a relatively high rate of LOH at 9p21 [68] [69] [63]. However, due the complex nature of the 9p21 loci containing also the p14ARF and p15INK4b tumor suppressors, it is difficult to score the true relevance of p16 in this loci loss. Furthermore, a high number of breast cell lines show abnormalities, including the spontaneously immortalized line MCF10A [65] [70]. In HESEC, p16 silencing by promoter methylation has been reported as one of the initial events occurring to allow cell proliferation, contributing to alleviate senescent checkpoint [71].

In our model, cyclin D1 amplification or p16 lost in breast tumors could be equivalent in maintaining CDK4 activity and therefore inactivating pRb checkpoint.

Taken together, our experiments suggest that although tumor proliferation may be blocked by the presence of wild type p53, p53-dependent senescence might not be the only tumor suppressor mechanism impeding tumorigenesis in the mammary glands of myrAKT transgenic mice. It seems that in this model, pRb pathway is more important checkpoint controlling senescence.
The cooperation observed between activated AKT and mutant p53 seems to indicate that AKT enhances proliferation of mutant p53-induced tumors

**Materials and Methods**

**Ethics Statement**

All animal experiments were done under the experimental protocol approved by the Institutional Committee for Care and Use of Animals of the Spanish National Cancer Research Centre which complies with European legislation on the care and use of animals, NIH guidelines for the use of laboratory animals, and related codes of ethic practice. The ethics committee for care of animals specifically approved this study.

**Generation and Analysis of Transgenic Mice**

Transgene construction is described in Blanco-Aparicio et al, 2007a. Transgenic mice were generated by the microinjection of the 4.7 kb fragment from the digested pMMTV-myrAKT1 with AatII+Sall (this fragment contains the MMTV promoter, myrAKT1 sequences and SV40 poly-adenylation signal) into the pronucleus of single-cell embryos isolated from super-ovulated B6/CBA mice, according to standard procedures by the Transgenic Unit, CNIO. Embryos that survived the microinjection were implanted into pseudo-pregnant females and allowed to develop to term. All the crosses where kept in C57BL/6J genetic background. Genotyping of the transgenic MMTV-myrAKT1 mice was performed by PCR of tail DNA. For details, see Blanco-Aparicio et al, 2006. p53 KO mice were obtained from Jackson laboratories. p27 were a kind gift of Dr. Manuel Serrano and p33mutant R172H were obtain from mouse models of human cancers consortium mouse repository.

**Whole Mounts**

Sacrificed females (human end point) and 3 days after weaning pregnant females were euthanized using CO2, and mammary glands were harvested, placed on dry, silanized glass slides and fixed overnight in 1:3:6 parts of glacial acetic acid:chloroform:100% ethanol. Tissues were rehydrated through successive incubations with 70% ethanol followed by distilled water, and stained with Carmine red alum overnight. Tissues were then dehydrated through successive incubations in graded ethanol followed by mixed xylene and mounted in Permount® (Fisher Scientific, Puerto Rico).

**Histopathology and Immunohistochemistry**

Mammary glands were fixed in 10% buffered formalin and embedded in paraffin. For histopathologic analysis, they were sectioned (2.5 µm) and stained with H&E. Slides were baked overnight at 55°C, deparaffinized in xylene, rehydrated, and washed with PBS. Epitope retrieval was performed in sodium citrate (pH6.1). Endogenous peroxidase activity was quenched with 1.5% hydrogen peroxide in methanol for 10 min and incubation (40 min) with the primary antibodies: anti-phosphoSer473AKT1 (Epitomics) diluted 1:175; anti-cytokeratin 6 (Covance) diluted 1:1000; anti-p63 (Thermo Scientific) 1:100; anti-nanog (Novus Biologicals) 1:50; anti-p27 (Thermo Scientific) diluted 1:125; anti-p19 (St Cruz Biotechnology) 1:50; anti-p21 (Santa Cruz Biotechnology) diluted 1:330;anti erbB2 (Spring Bioscience) diluted 1:15, rabbit polyclonal anti-p33 (Novocastra, Newcastle, UK) diluted 1:200; anti phosphoSI67ERα (New England Biolab) diluted 1:25; anti ER alpha (Master Diagnostica) prediluted; anti progesterone receptor (Thermo Scientific) prediluted, anti-E-cadherin (BD Transduction Laboratories,) diluted 1:150;anti p16 (St. Crz Biotechnology) diluted 1:75; horseradish peroxidase goat anti-rabbit IgG (Dako) diluted 1:50; horseradish peroxidase goat anti-mouse IgG (Jackson Immunoresearch, West Grove, PA) diluted 1:50; horseradish peroxidase rabbit anti-goat IgG (Dako) diluted 1:50. After incubation, immunodetection was carried out with the peroxidase-based PAP system (DAKO) using diaminobenzidine as substrate. Incubations omitting the specific antibody were used as a control of the technique.

**Western Blot Analysis**

Total protein was extracted from snap-frozen tissues by homogenization using a Dounce homogenizer in 1 ml extraction buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton-X100, 15 mM EDTA, 10 mM NaF, 2 mM TAME, 5 mM benzamidine, 10 µg/ml apronitin, 40 µg/ml bestatin, 10 µg/ml EA4, 300 µg/ml phosphoramidon, 50 µg/ml antipain, 2.5 mM NaP2O7, 15 mM pNPP, 1 mM DTT, 60 mM β-glycerophosphate, 10 µg/ml leupeptine, 0.14 µg/ml chymostatin, 0.7 µg/ml pepstatin, 1 ng/ml pefabloc and complete protease inhibitor cocktail tablet (Roche molecular Biochemicals, Spain). Homogenates were centrifuged at 10 000 g for 10 min at 4°C twice, and fat was removed from the surface. Final supernatants were analyzed by western blot as described previously (28).

**Statistical Analysis**

All statistics were analyzed using the SPSS statistical package (version 13.0 for Windows). Statistical analysis of tumor-free survival curves included calculation of Kaplan–Meier distributions of survival of two different groups of mice and comparison by a two-sided log-rang test. T de Student tests were conducted to test the different levels of expression of activated myrAKT, to test the different incidence of MIN, sucking differentiation and tumors in all the transgenic line vs wt mouse. Spearman rank testes were conducted to test the differential incidence of epithelial and non-epithelial tumors between the different groups of treated mice. A P-value of <0.05 was considered statistically significant.

Hierarchical clustering was performed using the function hclust (package amap) of the free statistical software R [72], as previously reported in [73]

**Supporting Information**

**Figure S1** Mammary gland involution is altered in transgenic females. The regression of the mammary glands of transgenic mice was compared with the mammary glands of wild-type littermates. The percentage of involuted mammary glands was determined 3 d after weaning of the first litter. Of each mouse, a whole mount preparation, followed by red carmine staining, was performed using the right hind leg mammary gland, whereas sections of the left hind leg mammary gland were stained with H&E or with the antibody against phosphorylated AKT. For all three transgenic mouse lines, a reduced involution of the mammary glands could be detected, which correlated with an elevated level of AKT phosphorylation.

Found at: doi:10.1371/journal.pone.0009305.s001 (0.95 MB PPT)

**Figure S2** Molecular characterization of MIN and mammary tumors in wt and myrAKT mice. Immunohistochemical staining of MIN and tumors with AKT Ser473, cytokerin 6, p63, progesterone receptor (PR), estrogen receptor alpha (ER) and phosphoSI67ERα. A 200× magnification was used and 400× magnification was inserted in the corner.

Found at: doi:10.1371/journal.pone.0009305.s002 (2.70 MB PPT)

**Figure S3** Expression of senescence markers in MIN of wt and myrAKT mice. Immunohistochemical staining of MIN with p19,
p21. A 200× magnification was used and 400× magnification was inserted in the corner.

**Figure S4** p27Kip1 is expressed in mammary gland lesions of myrAKT mice and its lost does not promote tumorigenesis. A) Immunohistochemical staining with p27 of wt normal mammary gland (a) and wt MIN (c) and myrAKT normal mammary gland (b), myrAKT Min (d), myrAKT tumors (e-f). A 200× magnification was used and 400× magnification was inserted in the corner B) Tumor-free survival curves in p27KO (+/-) and p27KO (+/-);myrAKT transgenic mice. Survival curves were computed using the Kaplan-Meier product-limit method. The numbers of mice are the following: p27KO (+/−) (n = 1); p27KO (+/−);myrAKT transgenic mice (n = 12). C) Mammary gland phenotypes of the myr AKT and p27 (+/−);myrAKT transgenic mouse lines observed after death. Whole mammary glands of sacrificed (human end point) mice were stained with carmine red to visualize the structure of the ducts and alveolae. Four different categories of phenotypes could be distinguished: (1) normal structure similar to the one of young virgin female mice; (2) Cystic dilatation (of the ducts) of more than 4 time; (3) increased number of ramifications and strongly increased alveolar size (4) Extreme alveolar hyperproliferation covering the space between the ducts to more than 70%. Points, median of each mouse branching observed.

**Figure S5** Survival and characterization of alteration in mammary gland of myrAKT transgenic mice in a heterozygous p53 (+/−) background. A) Tumor-free survival curves of p53 (+/−), myrAKT and the double transgenic p53(+/−);myrAKT transgenic mice. Survival curves were computed using the Kaplan-Meier product-limit method. The numbers of mice are the following: p53(+/−) (n = 32), p33(+/−);myrAKT(n = 49) and myrAKT (n = 12). B) Survival of mice that have developed mammary gland tumors. The numbers of mice are the following: p53(+/−)(n = 3); p53(+/−);myrAKT (n = 3). C) Incidence of preneoplastic and neoplastic lesions in p53(+/−) and p53(+/−);myrAKT transgenic mice.

**Acknowledgments**

The authors acknowledge the Comparative Pathology Unit of the CNIO for the histological and immunohistochemical work; the Transgenic Unit at the CNIO for the promemocie microinjection and the rederivation by embryo transfer; the Animal Facility Unit for the maintenance and care of the mice.

**Author Contributions**

Conceived and designed the experiments: CBA YC BP OR IF. Analyzed the data: CBA MC AC. Wrote the paper: AC.

**References**

1. Vivanco I, Sawyers CL. (2003) The phosphatidylinositol-3-kinase/AKT pathway in human cancer. Nat Rev Cancer 2: 459–501.
2. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, et al. (2005) Colorectal cancer: mutations in a signaling pathway. Nature 436: 792.
3. Liav D, Marsh DJ, Li J, Dahia PL, Wang SI, et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64–67.
4. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, et al. (1999) PTEN inactivation and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 8: 441–442.
5. Nelen MR, van Staveren WC, Peeters CA, Hasel MB, Gorlin R, et al. (1997) Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6: 1303–1307.
6. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M (1998) Clinical and pathological features of breast disease in Cowden’s syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 29: 47–53.
7. Samuel Y, Wang Z, Bardelli A, Silliman N, Pnak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 534–534.
8. Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol-3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102: 16099–16104.
9. Capen JD, Faber AL, Horn C, Donohoo GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439–444.
10. Bachman KE, Argani P, Samuels Y, Bardelli A, Silliman N, Pnak J, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772–775.
11. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7676–7681.
12. Kirkegaard T, Winton CJ, McGlynn LM, Toovey SM, Dunne B, et al. (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139–146.
13. Yang D, Orazi S (2005) A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A 102: 6936–6941.
14. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, et al. (2006) Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5: 779–785.
15. Assano T, Yao Y, Zhu J, Li D, Abbruzzese JL, et al. (2004) The PI3 kinase/Akt signaling pathway is activated due to aberrant Pen expression and targets transcription factors NF-kappaB and E-Myc in pancreatic cancer cells. Oncogene 23: 8571–8580.
16. Okano J, Snyder L, Rustgi AK (2003) Genetic alterations in esophageal cancer. Methods Mol Biol 222: 131–145.
17. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, et al. (2003) Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 63: 10199–10207.
18. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, et al. (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5065–5065.
19. Blanco-Aparicio C, Resner O, Leal JF, Carmen R, Carmen A (2007) PTEN, more than the AKT pathway. Carcinogenesis 28: 1379–1386.
20. Dowardal J (2004) PI3-kinase, Akt and cell survival. Semin Cell Dev Biol 15: 177–182.
21. Paz DR, Thompson CB (2005) Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435–7442.
22. Stiles B, Gilman V, Khamaznazar L, Resche R, Li A, et al. (2002) Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 22: 3842–3851.
23. Link W, Rosado A, Fontimaya J, Thomas JE, Carnero A (2005) Membrane localization of all class I PI 3-kinase isoforms suppresses E-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem 95: 979–989.
24. Xu J, Kattar Y, Wang C, Lau M, Jiao X, et al. (2007) Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A 104: 7438–7443.
25. Li G, Robinson GW, Lesche R, Martine-Diaz H, Jiang Z, et al. (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129: 4159–4170.
26. Renner O, Blanco-Aparicio C, Grassow M, Canamera M, Leal JF, et al. (2008) Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Res 68: 9643–9653.

27. Blanco-Aparicio C, Perez-Gallego I, Poqueno B, Leal JF, Renner O, et al. (2007) Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 28: 504–594.

28. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ (2001) Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21: 2203–2212.

29. Chen Z, Troman LC, Shaffer D, Lin HK, Dotan ZA, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Peru-deficient tumorigenesis. Nature 436: 725–730.

30. Sharpless NE, DePinho RA (2005) Cancer: crime and punishment. Nature 436: 636–637.

31. Majumder PK, Grisanzio C, O’Connell F, Mann B, Brito JM, et al. (2008) A prostatic intraepithelial neoplasia-dependent p57 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14: 146–155.

32. Collado M, Gil J, Efeyan A, Guerra G, Schuhmacher AJ, et al. (2005) Tumour biology: senescence in premalignant tumours. Nature 436: 642–645.

33. Moral M, Segrelles C, Lara MF, Martinez-Cruz AB, Lorz C, et al. (2009) Akt signaling synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. Cancer Res 69: 1199–1208.

34. Moral M, Segrelles C, Martinez-Cruz AB, Lorz C, Santos M, et al. (2009) Transgenic mice expressing constitutively active Akt in oral epithelium validate KLF4 as a potential biomarker of head and neck squamous cell carcinoma. In Vivo 23: 653–660.

35. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, et al. (2008) Akt regulation of p53-dependent cellular senescence of mammary tumors and metastasis. J Biol Chem 283: 10994–11008.

36. Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, et al. (2003) Effect of PTEN/AKT pathway in cancer research. Clin Transl Oncol 10: 618–627.

37. Carver BS, Pandolfi PP (2006) Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 12: 5305–5311.

38. Schade B, Rao T, Dourdin N, Lesurf R, Hallett M, et al. (2009) PTEN/AKT pathway in cancer research. Clin Transl Oncol 10: 618–627.

39.平整并建模Association of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 9: 5582–5588.

40. Dillon RL, White DE, Muller WJ (2007) The phosphatidyl inositol 3-kinase

41. Britt K, Ashworth A, Smalley M (2007) Pregnancy and the risk of breast cancer. Carcinogenesis 28: 191–202.

42. Cameron A (2009) The PKB/AKT Pathway in Cancer. Current Pharmacological Design 17: 1433–1449.

43. Plas DR, Thompson CB (2002) Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab 13: 75–78.

44. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zaghouan A, et al. (2006) Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9: 23–32.

45. Sotiriou C, Svahn J, Reivonen M, Pejcharova S, Stindl R, et al. (2005) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216: 399–407.

46. Iwakuma T, Lozano G (2007) Crippling p53 activities via knock-in mutations in the p53 response to oncogene-induced senescence. PLoS ONE 3: e3230.

47. Albrektsen G, Heuch I, Hansen S, Kvale G (2005) Breast cancer risk by age at menarche and age at first birth. Cancer Causes Control 16: 305–310.

48. Iwakuma T, Lozano G (2007) Crippling p53 activities via knock-in mutations in the p53 response to oncogene-induced senescence. PLoS ONE 3: e3230.